These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20024640)

  • 41. [The JUPITER study: critical review of final results].
    Urbinati S; Romanazzi S; Gambetti S
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):28S-32S. PubMed ID: 21298859
    [TBL] [Abstract][Full Text] [Related]  

  • 42. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians.
    Windgassen EB; Funtowicz L; Lunsford TN; Harris LA; Mulvagh SL
    Postgrad Med; 2011 Jan; 123(1):114-9. PubMed ID: 21293091
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The JUPITER study: background and research hypotheses].
    Rapezzi C; Gallo P
    G Ital Cardiol (Rome); 2009 Dec; 10(11-12 Suppl 3):25S-27S. PubMed ID: 21298858
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High-sensitivity C reactive protein and risk of cardiovascular disease in China-CVD study.
    Dong Y; Wang X; Zhang L; Chen Z; Zheng C; Wang J; Kang Y; Shao L; Tian Y; Wang Z;
    J Epidemiol Community Health; 2019 Feb; 73(2):188-192. PubMed ID: 30530521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean?
    Shishehbor MH; Hazen SL
    Cleve Clin J Med; 2009 Jan; 76(1):37-44. PubMed ID: 19122109
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Beyond Coronary Calcification, Family History, and C-Reactive Protein: Cholesterol Efflux Capacity and Cardiovascular Risk Prediction.
    Mody P; Joshi PH; Khera A; Ayers CR; Rohatgi A
    J Am Coll Cardiol; 2016 May; 67(21):2480-7. PubMed ID: 27230043
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of C-reactive protein in coronary risk reduction: focus on primary prevention.
    Gotto AM
    Am J Cardiol; 2007 Mar; 99(5):718-25. PubMed ID: 17317380
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study.
    Fonseca FA; Izar MC
    Expert Rev Cardiovasc Ther; 2009 Sep; 7(9):1041-56. PubMed ID: 19764857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inflammatory and Cholesterol Risk in the FOURIER Trial.
    Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
    Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 52. High-density lipoprotein cholesterol, high-sensitivity C-reactive protein, and cardiovascular disease in United States adults.
    Bilhorn KR; Luo Y; Lee BT; Wong ND
    Am J Cardiol; 2012 Nov; 110(10):1464-7. PubMed ID: 22858184
    [TBL] [Abstract][Full Text] [Related]  

  • 53. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study.
    Wilson PW; Nam BH; Pencina M; D'Agostino RB; Benjamin EJ; O'Donnell CJ
    Arch Intern Med; 2005 Nov; 165(21):2473-8. PubMed ID: 16314543
    [TBL] [Abstract][Full Text] [Related]  

  • 54. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. Preventive Services Task Force.
    Buckley DI; Fu R; Freeman M; Rogers K; Helfand M
    Ann Intern Med; 2009 Oct; 151(7):483-95. PubMed ID: 19805771
    [TBL] [Abstract][Full Text] [Related]  

  • 55. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention.
    Ridker PM
    Am J Cardiol; 2003 Aug; 92(4B):17K-22K. PubMed ID: 12948872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
    Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
    Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cumulative Exposure to High-Sensitivity C-Reactive Protein Predicts the Risk of Cardiovascular Disease.
    Wang A; Liu J; Li C; Gao J; Li X; Chen S; Wu S; Ding H; Fan H; Hou S
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29066453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The clinical utility of high-sensitivity C-reactive protein in cardiovascular disease and the potential implication of JUPITER on current practice guidelines.
    Mora S; Musunuru K; Blumenthal RS
    Clin Chem; 2009 Feb; 55(2):219-28. PubMed ID: 19095730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. C-reactive protein: a novel marker of cardiovascular risk.
    Shah SH; Newby LK
    Cardiol Rev; 2003; 11(4):169-79. PubMed ID: 12852794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.